Oncolytics Biotech® Announces Upcoming Presentations at Investor Conferences
Oncolytics Biotech Inc. (NASDAQ: ONCY) announced its participation in two investor conferences in September 2020. Dr. Matt Coffey, CEO, will present at the LD Micro 500 Virtual Investor Conference on September 3, 2020, at 4:20 pm ET, followed by a presentation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 2:00 pm ET. Investors can join these webcasts via the links provided. The company is advancing its cancer treatment, pelareorep, which shows promise in enhancing tumor response.
- None.
- None.
SAN DIEGO and CALGARY, Alberta, Sept. 1, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be presenting a corporate overview at the following investor conferences in September:
LD Micro 500 Virtual Investor Conference
Presenter: Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc.
Date: Thursday, September 3, 2020
Time: 4:20 pm ET
Webcast Link: Available here
H.C. Wainwright 22nd Annual Global Investment Conference
Presenter: Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc.
Date: Tuesday, September 15, 2020
Time: 2:00 pm ET
Webcast Link: Available here
Company management will also be participating in one-on-one investor meetings at both conferences. To schedule a meeting please submit a meeting request on the website for each respective conference, or email tim@lifesciadvisors.com.
Live webcasts of the Company's presentations will also be available on the Investor Relations page of Oncolytics' website (LINK) and will be archived for three months.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements, including the Company's belief as to the potential and mode of action of pelareorep as a cancer therapeutic, and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Company may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.
Company Contact Kirk Look Chief Financial Officer 403.670.7658 | Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors 212.915.2564 |
View original content:http://www.prnewswire.com/news-releases/oncolytics-biotech-announces-upcoming-presentations-at-investor-conferences-301122025.html
SOURCE Oncolytics Biotech® Inc.
FAQ
What are the dates for Oncolytics Biotech's presentations at investor conferences?
Who is presenting for Oncolytics Biotech at the upcoming investor conferences?
What is the focus of Oncolytics Biotech's presentations?
How can investors access the webcasts of Oncolytics Biotech's presentations?
What is pelareorep developed by Oncolytics Biotech?
